Clinical trials: Acinetobacter Baumannii
Acinetobacter Baumannii Infection
Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection
The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.
- Trial name
- NCT02886637
- Testing
- None intervention
- Volunteers
- 40 people
- Sponsor
- Southeast University, China
Pneumonia, Ventilator-Associated, Colistin Adverse Reaction
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
This study is planned to compare the clinical efficacy and safety of aerosolized plus intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of ventilator-associated pneumonia (VAP) due to…
- Conditions
- Pneumonia, Ventilator-Associated, Colistin Adverse Reaction, Infection Due to Multidrug Resistant Acinetobacter, Infection Resistant to Multiple Drugs
- Trial name
- NCT02806141
- Testing
- Aerosolized plus intravenous colistin, Intravenous colistin
- Where
- Thailand
- Volunteers
- 204 people
- Sponsor
- Hat Yai Medical Education Center
Multi-antibiotic Resistance
Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
The goal of this observational study is to evaluate the screening for multidrug resistant bacteria in patients admitted to hospitals in Scania.
- Trial name
- NCT06370299
- Testing
- (exposure of) MDR carriage
- Volunteers
- 10,000 people
- Sponsor
- Region Skane
Infections, Nosocomial, Infections, Respiratory Tract
Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated From Patients With Hospital Acquired Infections in Sohag University Hospitals, Egypt
A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft…
- Trial name
- NCT06628076
- Testing
- Culture specific antibiotic therapy, Antibiotic, Biofilm assessment
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Osteomyelitis
Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Acinetobacter baumannii is an opportunist pathogen that has become increasingly important over recent years as a cause of nosocomial infections.
- Trial name
- NCT03559530
- Testing
- Antimicrobial
- Where
- Brazil
- Volunteers
- 262 people
- Sponsor
- University of Sao Paulo
Acinetobacter Bacteraemia
A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii Bacteremia
Extensively and multi-drug resistant A. baumannii (AB) represent an emerging threat in hospitals locally and worldwide. There is lack of prospective comparative clinical data to guide optimal strategy for treating such…
- Trial name
- ANTI-AB (NCT01511224)
- Where
- 3 sites in Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Infections Resistant to Multiple Drugs, Bacterial Infections
Multi-Drug Resistant Organism Network
This study is specifically designed to provide observational data which can be used to help in the design of future randomized clinical trials on both therapeutics and diagnostics for MDRO infections.
- Trial name
- MDRO Network (NCT03646227)
- Testing
- Standard of Care
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 6,496 people
- Sponsor
- Duke University
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate…
- Trial name
- NCT06801223
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Innoviva Specialty Therapeutics
Carbapenem Resistant Bacteria Infection
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
Among antibiotic-resistant organisms, the Gram-negative bacteria are now the most important challenge because of the rapid worldwide spread of mechanisms conferring resistance to multiple drugs.
- Trial name
- EURECA (NCT02709408)
- Where
- 50 sites in Albania, Bulgaria and 9 more
- Volunteers
- 2,515 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Acinetobacter Infections
Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical
The present study was designed to study the impact of empirical treatment with colistin empirical monotherapy and combined treatment with tigecycline and vancomycin on mortality of bacteremia Multiresistant Acinetobacter…
- Trial name
- NCT02573064
- Testing
- Colistin, Tigecycline, Vancomycin
- Volunteers
- 113 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Carbapenem-Resistant Enterobacteriaceae
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
The primary purpose of this clinical investigation is to establish the performance of the GenePOC Carba assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Carbapenemase…
- Trial name
- NCT03680898
- Testing
- Rectal swab collection
- Where
- 3 sites in United States, Canada
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
- Trial name
- CASCADE (NCT05922124)
- Testing
- Cefiderocol, Ampicillin-sulbactam, Colistin
- Where
- 3 sites in Israel
- Volunteers
- 734 people
- Sponsor
- Rambam Health Care Campus